Literature DB >> 22784424

Effects of the standardized Ginkgo biloba extract EGb 761® on neuroplasticity.

Walter E Müller1, Jeanine Heiser, Kristina Leuner.   

Abstract

Neuroplasticity, the ability of synapses to undergo structural adaptations in response to functional demand or dysfunctions is increasingly impaired in aging and Alzheimer's disease. EGb761® has been shown in several preclinical reports to increase nearly all aspects of impaired neuroplasticity (long-term potentiation, spine density, neuritogenesis, neurogenesis). While all three fractions of constituents (ginkgolides, flavonoids, bilobalide) seem to be active, the flavonoids and specifically the aglycone isorhamnetin seem to be most relevant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22784424     DOI: 10.1017/S1041610212000592

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  14 in total

1.  Inhibitory effects of EGb761 on the expression of matrix metalloproteinases (MMPs) and cartilage matrix destruction.

Authors:  Xuewen Wang; Xingshen Zhao; Shusen Tang
Journal:  Cell Stress Chaperones       Date:  2015-06-05       Impact factor: 3.667

Review 2.  Effects of polyphenols on brain ageing and Alzheimer's disease: focus on mitochondria.

Authors:  Sebastian Schaffer; Heike Asseburg; Sabine Kuntz; Walter E Muller; Gunter P Eckert
Journal:  Mol Neurobiol       Date:  2012-06-17       Impact factor: 5.590

Review 3.  Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.

Authors:  Gunter P Eckert; Kathrin Renner; Schamim H Eckert; Janett Eckmann; Stephanie Hagl; Reham M Abdel-Kader; Christopher Kurz; Kristina Leuner; Walter E Muller
Journal:  Mol Neurobiol       Date:  2012-05-03       Impact factor: 5.590

4.  Neuroprotective effects of Ginkgo biloba extract and Ginkgolide B against oxygen-glucose deprivation/reoxygenation and glucose injury in a new in vitro multicellular network model.

Authors:  Xiaohan Yang; Tiezheng Zheng; Hao Hong; Nan Cai; Xiaofeng Zhou; Changkai Sun; Liying Wu; Shuhong Liu; Yongqi Zhao; Lingling Zhu; Ming Fan; Xuezhong Zhou; Fengxie Jin
Journal:  Front Med       Date:  2017-10-02       Impact factor: 4.592

5.  EGb761 provides a protective effect against Aβ1-42 oligomer-induced cell damage and blood-brain barrier disruption in an in vitro bEnd.3 endothelial model.

Authors:  Wen-bin Wan; Lan Cao; Lu-mei Liu; Bill Kalionis; Chuan Chen; Xian-tao Tai; Ya-ming Li; Shi-jin Xia
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

6.  Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report.

Authors:  Régis Bordet; Ralf Ihl; Amos D Korczyn; Giuseppe Lanza; Jelka Jansa; Robert Hoerr; Alla Guekht
Journal:  BMC Med       Date:  2017-05-24       Impact factor: 8.775

Review 7.  Ginkgo biloba extract EGb 761® alleviates neurosensory symptoms in patients with dementia: a meta-analysis of treatment effects on tinnitus and dizziness in randomized, placebo-controlled trials.

Authors:  Rainer Spiegel; Roger Kalla; Georgios Mantokoudis; Raphael Maire; Heiko Mueller; Robert Hoerr; Ralf Ihl
Journal:  Clin Interv Aging       Date:  2018-06-13       Impact factor: 4.458

Review 8.  A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions.

Authors:  Anil Kumar; Arti Singh
Journal:  Front Pharmacol       Date:  2015-09-24       Impact factor: 5.810

9.  Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine.

Authors:  Larysa Sokolova; Robert Hoerr; Tamara Mishchenko
Journal:  Int J Otolaryngol       Date:  2014-06-25

10.  Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment - a randomized double-blind placebo-controlled trial.

Authors:  Stefanie M Beck; Hannes Ruge; Christoph Schindler; Martin Burkart; Robert Miller; Clemens Kirschbaum; Thomas Goschke
Journal:  Hum Psychopharmacol       Date:  2016-05       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.